WC
EUCRU

Wealthspring Capital’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Wealthspring Capital’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-130,290
Closed -$1.31M – 366
2022
Q3 		$1.31M Buy
130,290
+218
+0.2% +$2.17K 0.26% 129
2022
Q2 		$1.29M Sell
130,072
-8,301
-6% -$82.4K 0.24% 135
2022
Q1 		$1.36M Buy
138,373
+13,309
+11% +$132K 0.27% 127
2021
Q4 		$1.25M Sell
125,064
-636
-0.5% -$6.39K 0.27% 138
2021
Q3 		$1.25M Buy
125,700
+8,646
+7% +$86.4K 0.3% 123
2021
Q2 		$1.19M Hold
117,054
– – 0.3% 117
2021
Q1 		$1.18M Sell
117,054
-12,826
-10% -$137K 0.32% 92
2020
Q4 		$1.39M Buy
+129,880
New +$1.32M 0.69% 57

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $10.3B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $6.41B AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $17.8B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return